title: Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.
authors.affiliation: Profil, Neuss, Germany sabine.arnolds@profil.com.
authors.forename: Sabine
authors.initials: S
authors.lastname: Arnolds
authors.affiliation: Institute for Health Economics and Clinical Epidemiology, Medical Faculty of the University of Cologne, Cologne, Germany.
authors.forename: Peter T
authors.initials: PT
authors.lastname: Sawicki
mesh_terms: D019610:Cytoprotection; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1